How do we know what we think we know? In pediatric neurogenetics and the epilepsies, evidence isn’t static: it grows, it shifts, and it often reveals new uncertainties even as it claims new certainties. The posts below explore how we interpret genomic data, how variant classification frameworks evolve, and why precision medicine sometimes teaches us lessons through unexpected outcomes. This archive includes posts from 2022 and later; it does not include older posts on these themes.

Figure 1. Visualizing the new ACMG/AMP points-based classification system. The diagram shows how different combinations of evidence criteria contribute to variant interpretation under the updated framework. Each bar represents a typical evidence scenario, broken down by individual ACMG/AMP rules such as PVS1 (very strong), PS2–PS4 (strong), PM1–PM6 (moderate), and PP1–PP5 (supporting). Conflicting evidence is indicated by hatched bars, highlighting situations where pathogenic and benign signals pull in opposite directions. Colored background zones indicate the thresholds that define final classifications: Pathogenic (≥10 points), Likely Pathogenic (6–9 points), VUS (0–5 points), Likely Benign (−1 to −6 points), and Benign (≤−7 points, or BA1 as a stand-alone benign criterion). This new quantitative framework turns what once felt like a “word salad” of rules into a transparent and teachable scoring system, marking a quiet revolution in how we approach clinical variant interpretation.

Variant Classification & Interpretation Frameworks

• The quiet revolution – revising ACMG criteria for epilepsy genes
  A clinic-to-bench reflection on how evolving precision therapy frameworks are motivating refinement of variant interpretation criteria — and why “variant of uncertain significance” can become a barrier to care even when biology points elsewhere.

• The power of paralogs in epilepsy genetics
  Exploring how integrating information from paralogous gene positions can strengthen variant interpretation and how this evidence is being incorporated into ACMG/AMP criteria.

• Why variants of uncertain significance need explanatoriness
  A nuanced discussion of what it means for a VUS to be interpretable and how explanatory frameworks can complement strict classification schemes.

Lessons from Clinical Experience & Precision Medicine

• Precision medicine is instructive when it fails
  Insights from the epilepsy community on how early precision medicine efforts (e.g., quinidine in KCNT1 disorders) revealed not failure, but weaknesses in how we frame and apply targeted therapies — and what those lessons mean for interpreting genetic evidence.

• Epilepsy genetics is more than just sending gene panels
  A reminder that accurate interpretation requires more than choosing tests; it requires contextual understanding, clinical integration, and thoughtful consideration of how and when genetic evidence influences decisions.

What you need to know. This collection highlights the interpretive layer of genetic evidence in pediatric neurogenetics — the place where data meets judgment, and where frameworks evolve because the biology and the clinical needs demand it. These posts focus on how we navigate uncertainty, build stronger criteria, and align variant interpretation with real-world clinical challenges.